Bhm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Hauske SJ, Schueler E, Wanner C, Verma S, Zannad F, Packer M, Anker SD
Decreased appetite and cravings, making it easier to maintain healthy eating habits
Sponsors have always been required to hold a DOC on file, but this will now be required to be submitted as part of the application
However, retatrutide is a first-in-class triple agonist (targeting GIP, GLP-1, and glucagon receptors simultaneously), which may lead to more cautious FDA review compared to drugs with established mechanisms
Retatrutide Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors, offering a broader metabolic response compared to tirzepatide
B., Kanters S., Khurana R., Kissock J., Severin N., Stafford S